Haixiang Pharmaceutical announced that its wholly-owned subsidiary, Chuannan Pharmaceutical, recently received the “Veterinary Drug Production License” and “Veterinary Drug GMP Certificate” from the Zhejiang Provincial Department of Agriculture and Rural Affairs, which are valid until May 17, 2027, and the scope of production and acceptance is non-sterile raw materials, flunixin glucamine). This marks that the new production line has entered the commercial operation stage and expanded the company's fluorfenicol production capacity reserves. However, pharmaceutical production and sales are affected by factors such as industry policies and market environment, and there is uncertainty.

Haixiang Pharmaceutical announced that its wholly-owned subsidiary, Chuannan Pharmaceutical, recently received the “Veterinary Drug Production License” and “Veterinary Drug GMP Certificate” from the Zhejiang Provincial Department of Agriculture and Rural Affairs, which are valid until May 17, 2027, and the scope of production and acceptance is non-sterile raw materials, flunixin glucamine). This marks that the new production line has entered the commercial operation stage and expanded the company's fluorfenicol production capacity reserves. However, pharmaceutical production and sales are affected by factors such as industry policies and market environment, and there is uncertainty.